New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
10:04 EDTRPTP, TSH, VTSS, ETN, OAS, CSGS, AGCO, MYGN, TGI, ITC, ANGI, BBG, SYT, SIRI, CENX, BIRTOn the Fly: Analyst Downgrade Summary
AGCO (AGCO) downgraded to Market Perform from Outperform at BMO Capital... Actuate (BIRT) downgraded to Hold from Buy at Drexel Hamilton... Angie's List (ANGI) downgraded to Neutral from Buy at BofA/Merrill... CSG Systems (CSGS) downgraded to Underweight from Neutral at JPMorgan... Century Aluminum (CENX) downgraded to Market Perform from Outperform at Cowen... ITC Holdings (ITC) downgraded to Neutral from Buy at ISI Group... Oasis Petroleum (OAS) downgraded to Buy from Conviction Buy at Goldman... Sirius XM (SIRI) downgraded to Hold from Buy at Wunderlich... Triumph Group (TGI) downgraded to Neutral from Buy at BofA/Merrill... James River Coal (JRCC) downgraded at Sterne Agee... Eaton (ETN) downgraded at MKM Partners... Syngenta (SYT) downgraded to Buy from Conviction Buy at Goldman... Myriad Genetics (MYGN) downgraded to Neutral from Buy at Ladenburg... Vitesse (VTSS) downgraded to Hold from Buy at Craig-Hallum... Bill Barrett (BBG) downgraded to Neutral from Accumulate at Global Hunter... Teche Holding (TSH) downgraded to Market Perform from Outperform at Fig Partners... Raptor Pharmaceuticals (RPTP) downgraded to Underperform from Neutral at Wedbush.
News For AGCO;BIRT;ANGI;CSGS;CENX;ITC;OAS;SIRI;TGI;ETN;SYT;MYGN;VTSS;BBG;TSH;RPTP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 20, 2015
07:41 EDTMYGNAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
05:17 EDTMYGNMyriad EMPATHY-P clinical study results to be highlighted at annual congress
Myriad Genetics announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. The EMPATHY-P study evaluated the Prolaris test on 525 patient biopsy samples to determine the aggressiveness of prostate cancer in these newly diagnosed patients from five European countries including: Italy, Germany, Spain, Switzerland and the UK. The patients' biopsy samples also were evaluated using standard clinical pathology methods, which were then compared to the Prolaris test results. The EMPATHY-P data showed, overall, that the Prolaris test found 42% of the European men evaluated had a risk profile that was either lower or higher than would be expected using clinical pathology. Interestingly, this finding is consistent with the previously published U.S. Prostate Biopsy Research study, which found 51% of U.S. patients had a risk profile that differed from clinical pathology.
March 19, 2015
10:02 EDTVTSSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:53 EDTVTSSVitesse downgraded to Hold from Buy at Craig-Hallum
Subscribe for More Information
07:10 EDTETNEndeavor IP subsidiary enters into license, settlement agreement with Eaton
Subscribe for More Information
06:25 EDTVTSSVitesse downgraded to Hold from Buy at Topeka
Subscribe for More Information
March 18, 2015
16:26 EDTVTSSOn The Fly: Closing Wrap
Subscribe for More Information
15:47 EDTCENXCentury Aluminum upgraded to Buy from Hold at Standpoint Research
Subscribe for More Information
12:38 EDTVTSSOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday ahead of the conclusion of the Federal Reserve's latest rate setting meeting and the central bank's accompanying announcements. The averages began the session in negative territory and have been range-bound throughout the morning. The Dow was down triple digits once again, making 8 consecutive days that the blue chip index has seen a triple digit move. ECONOMIC EVENTS: In the U.S., the DOE petroleum inventory reports showed a 9.6M barrel rise in crude stocks in the week of March 13, versus expectations for a 4.4M build. The day's big economic news is yet to come, with the Fed's FOMC meeting announcement due at 2:00 pm EDT and Fed Chair Yellen holding a press conference a half hour later. Elsewhere, Prime Minister Benjamin Netanyahu unexpectedly defeated his main challenger in Israelís election and his Likud party appears set to capture more parliament seats. COMPANY NEWS: Shares of FedEx (FDX) slid 2.5% after the shipping giant reported earnings that beat estimates, but revenue that fell short of the consensus forecast, for its third fiscal quarter. FedEx noted that it expects to deliver "record" yearly earnings for the current fiscal year and next fiscal year as well... Oracle (ORCL) shares rose 2.5% after the company's third quarter profits matched expectations and it raised its quarterly dividend 25%. MAJOR MOVERS: Among the notable gainers was Vitesse Semiconductor (VTSS), which jumped 37% after the company agreed to be acquired for $5.28 per share in cash by Microsemi (MSCC). Also higher was Retrophin (RTRX), which rose 28% after the company said it will exercise its right to purchase from Asklepion Pharmaceuticals all worldwide rights, titles, and ownership of Cholbam after the FDA approved the drug for the treatment of pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for patients with peroxisomal disorders. Among the noteworthy losers was Willbros Group (WG), which dropped 55% and was downgraded to Underperform at DA Davidson after announcing its earnings report will be delayed and the company is in potential non-compliance with debt covenants. Also lower following their earnings reports were Nektar Therapeutics (NKTR), which fell 15% after the company's Phase III BEACON metastatic breast cancer study missed its primary endpoint. INDEXES: Near midday, the Dow was down 105.02, or 0.59%, to 17,744.06, the Nasdaq was down 12.45, or 0.25%, to 4,924.99, and the S&P 500 was down 7.69, or 0.37%, to 2,066.59.
10:58 EDTANGIAngie's List calls active on speculation the company canceled a conference
Subscribe for More Information
10:44 EDTANGIRumor: Angie's List active on speculation the company canceled a conference
Subscribe for More Information
10:28 EDTVTSSVitesse downgraded to Hold from Buy at Benchmark Co.
Subscribe for More Information
09:23 EDTVTSSOn The Fly: Pre-market Movers
Subscribe for More Information
07:29 EDTVTSSNorthland Capital Markets to hold a conference
Subscribe for More Information
07:07 EDTVTSSMicrosemi to acquire Vitesse Semiconductor for $389M
Subscribe for More Information
March 17, 2015
10:00 EDTBBGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:13 EDTBBGBill Barrett downgraded to Sell from Neutral at Global Hunter
Subscribe for More Information
07:20 EDTANGIBofA/Merrill to hold a conference
Smid Cap Conference 2015 is being held in Boston on March 17-18.
07:18 EDTMYGNMyriad Genetics announces collaboration expansion with BioMarin
Myriad Genetics (MYGN) announced an expansion of the company's collaboration with BioMarin Pharmaceutical (BMRN). Under the expanded collaboration, BioMarin will use Myriad's myChoice HRD companion diagnostic test to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive to talazoparib. Financial terms were not disclosed.
07:13 EDTETNBofA/Merrill to hold a conference
Global Industrials & EU Autos Conference 2015 to be held in London, England on March 17-20.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use